Human Growth Hormone (hGH) Clinical Evidence Guide: 2026 Medical Standards

Key Takeaways

• hGH approved only for adult GH deficiency and severe cachexia
• Therapeutic dose ranges 0.2‑0.6 mg/day; supraphysiologic doses cause severe side effects
• Strong evidence: lean mass gain and visceral fat loss in AGHD
• No proven lifespan extension; high IGF‑1 linked to reduced longevity
• Off‑label anti‑aging use is illegal in the United States

Pulse Analysis

Regulatory bodies have tightened oversight of recombinant human growth hormone, classifying it as a Schedule III‑equivalent biologic in most jurisdictions. This status reflects the drug’s potent anabolic properties and the narrow therapeutic window that separates clinical benefit from serious adverse events. By limiting approved indications to adult growth hormone deficiency and severe cachexia, agencies aim to protect patients from the growing market of illicit anti‑aging and bodybuilding applications that bypass safety monitoring.

The 2026 consensus separates the clinical data into three evidence tiers. Strong evidence demonstrates that physiologic replacement restores lean body mass, reduces visceral adiposity, and accelerates fracture or severe‑burn healing through enhanced collagen synthesis. Moderate evidence suggests improvements in cardiovascular risk markers and quality‑of‑life metrics, while limited or negative evidence debunks claims of muscle hypertrophy in eugonadal adults and any extension of maximal lifespan. These distinctions guide prescribers in setting realistic expectations and in selecting patients who truly benefit from IGF‑1‑mediated anabolic pathways.

Metabolic risk management remains the cornerstone of safe hGH therapy. Even at approved doses (0.2‑0.6 mg/day), the hormone’s anti‑insulin effect can provoke hyperglycemia, necessitating careful monitoring of serum IGF‑1 and glucose levels. Supraphysiologic regimens—common in illicit settings—exacerbate insulin resistance, trigger edema, carpal‑tunnel syndrome, and organomegaly, and often require adjunctive insulin therapy. As research explores selective IGF‑1 analogs and secretagogue peptides, clinicians must balance emerging alternatives against the proven, albeit limited, benefits of hGH for genuine deficiency states.